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Cryptococcosis is an acquired immune deficiency syndrome





 The remaining cases are comprised in the
group of immunocompromised subjects with other diseases





 Only rare cases of immunocompetent
subjects are described as developing the infection.





 in a 51-year-old human immunodeficiency
virus (HIV)-negative man. Cutaneous cryptococcosis was the
presenting sign of disseminated infection involving the central
nervous system manifesting in the form of meningoencephalitis
cryptococcica. The man was a surveyor who had done active
field-work for many years. Except for being an avid consumer of
alcohol, he had no unusual habits; there was no obvious under-
lying cause of immunosuppression. Two months prior to admis-
sion the man had noticed an ulceration on his back that he had
treated with hydrocycline; the ulcer had enlarged and additional
cutaneous lesions had developed elsewhere. On examination
we saw a large erythemolivid plaque in the middle of the man’s
back. The plaque had a tumour-like appearance with central
ulceration and raised and ‘rolled’ edges. Numerous satellite,
papulonodular lesions were noted with two distinct aspects;
some had a central area of superficial necrosis, with crusting
and comedo-like aspect, while others were shiny, dome-shaped,
aggregated, with central umbilication, resembling the lesions
of molluscum contagiosum (fig. 1). Several similar small lesions
were observed in the axillae and on the neck and face. There was
no lymphadenopathy and no involvement of the mucosae.
Routine biochemical and haematological analyses were
normal. Serological markers for hepatitis A, B, and C, Cytome-
galovirus, Epstein-Barr and HIV viruses, were all negative; the
T-helper/T-suppressor ratio was also normal. A chest X-ray
revealed subsegmental consolidation in the right hemithorax
supradiaphragm with interstitial fibrosis, but the man refused
further investigations for this chest finding. Histological exam-
ination using haematoxylin and eosin staining showed two
forms of tissue reaction in the same skin specimen, i.e. granu-
loma and gelatinous form. With the periodic acid-Schiff stain,
the yeast cells stained positively red (fig. 2) and with alcian blue
the organisms stained blue (the pathogen capsule stained dark
blue) and were seen contained in cystic formations. A presump-




 was confirmed by isolation of





after taking the skin smears. Biochemical identification of the





 was detected and confirmed sensitive to both ampho-
tericin B and 5-fluorcytosine. Soon after the man’s condition
worsened; in particular, he experienced severe headaches and
vision problems and he was transferred to the infectious dis-
eases ward. Meningoencephalitis cryptococcica was diagnosed.
Cryptococcosis is a rare infection in non-immunocompromised
individuals. Except for the man’s chronic alcohol abuse and
undetermined pulmonary problems, no other obvious cause
for immunosuppression could be found. We were unable to
determine the source of the infection, although we believe it
was work related, as the man’s occupation offered numerous





 (an encapsulated yeast and primary aetio-





isolated from soil world-wide, usually in association with bird





fig. 1 A large tumour-like plaque with central ulceration and small satellite
papulonodular lesions resembling those of molluscum contagiosum.
fig. 2 Histological picture (periodic acid-Schiff staining) showing numerous

















of airborne yeast and/or basidiospores is the main route of
infection. In particular, the man’s occupation gives two equally
likely possibilities for the probable site of entry of the pathogen,
namely, inhalation or a skin wound. If we had had the chance to
determine whether the man had already developed systemic
infection when he first noticed the lesion on his back, it would
have been easier to determine the possible site of entry. In par-
ticular, no fungaemia at the time of the emergence of the first
cryptococcal lesion, and localized cutaneous lesions could pro-









 as the symp-
toms of the systemic infection worsened soon after the first
lesion was observed (2 months), and the cryptococcal lesions
were scattered and emerged soon after the first one, we believe
that this man had secondary cutaneous cryptococcosis.
Furthermore, what makes this case unique is the fact that the
fungaemia (cryptococcaemia) and cutaneous cryptococcosis





which there is a paucity of data in the literature. For instance,
there are only a few published cases of cutaneous, pulmonary,




 infections, in AIDS




This case points out the clinical presentation and character-
istics of cutaneous cryptococcosis as monitory manifestation of
a disseminated cryptococcal infection, in addition to the ‘silent’
pulmonary alterations. As scattered cryptococcal lesions are
indicators of disseminated infection, they are crucial signs for
early and accurate diagnosis of a potentially serious and even
fatal disease.
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 is a superficial mycosis caused by dermatophytes,
filamentous fungi that invade keratinized structures of the skin
and adjoining structures, affecting the scalp and sometimes
extending to the eyelashes and eyebrows. These fungi pro-





slight to inflammatory, supurating lesions, depending on the





 is a common childhood affliction




 although a few cases have been














 depending on the geographical location.
There is also a difference in temporal incidence as, for example,









, which are currently
rare. The most prevalent forms in southern Spain are now










We report the case of a patient who was a 77-year-old male
with no significant family history and a personal history of
















dexamethasone, 10 mg/6 h morphine sulphate, 40 mg daily
omeprazole and 30 mg/12 h methotrexate. The patient pre-
sented due to several small balding spots, some merging
together to form a large patch and having suppurating lesions
(fig. 1). These patches were spread throughout the scalp and
beard and had been present for several months. In the sub-
maxillary region there were small unattached adenopathies. He
had been treated with oral antibiotics and topical antiseptics,
with no clinical improvement of the lesions. The patient claimed
to have no direct contact with domestic animals and stated
there were no similar lesions in family members. The clinical
exploration revealed numerous alopecic areas in the vertex area of
the scalp and a very large alopecic patch 4–5 cm in diameter in
the temporoparietal zone. This spot had broken-off hairs that
were easily plucked and papulovesicular eruptions with honey-
coloured scabs in the central part, together with follicular pustules.
Based on the clinical diagnosis of adult tinea capitis, a sample
was taken for culture and mycological study. Direct examina-





with endothrix-type hair shaft infection and raised, compact
colonies, finely branching out and dark violet in colour.
Numerous clamidospores were found microscopically. With the
clinical and mycological diagnosis of adult tinea capitis, we ini-
tiated treatment with 250 mg/day oral terbinafine and topical
terbinafine cream at two applications a day. A month after the
start of treatment, there was a considerable improvement of
the lesions, but the alopecic zones persisted. Treatment was
extended for 4 months for his immune status, by which time the
cure was completed and the affected zones began to show
regrowth of hair. Regrowth was completed by 6 months, with
no sequelae from the lesions (fig. 2).
In southern Spain, infection of the scalp by superficial fungi
is extremely rare in adults. Incidence ranges from 0.31% to
4.37% of the total dermatophytoses of the scalp in this part of
Spain, with a clear predominance in postmenopausal women.
For a fungus to be able to develop an infection, an individual
must have various predisposing factors and/or several circum-
stances favouring it, such as: (a) alteration of the cutaneous
mucous membrane: traumatism and maceration of the area;
(b) decompensated chronic illnesses, such as diabetes mellitus;








 is more prevalent in children since in adults
the lipidic layer of the hair contains saturated fatty acids, which
have a fungicidal action, this sebum secretion is hormone
dependent and does not begin until puberty; (e) inadequate
hygiene-sanitary measures; (f ) climatic factors, such as exces-
sive dampness and (g) the taking of medication: corticosteroids,
immunosuppressants and systemic antibiotics. Several authors
have postulated that some endocrine alterations cause an
abnormal sebum composition that facilitates infection of the






 is considered to be the species most















 although more prevalent in north Africa, the Mid-
dle East, India and Eastern Europe. This fungus is the causative
agent of tinea capitis in both children and adults and occasion-
ally of tinea corporis and tinea unguium as well. Direct exam-
ination of the hair reveals endothrix infection of the hair, with
septate hyphae and scaly arthroconidias. It is cultivated in
Sabouraud’s glucose agar (SGA). The colonies grow slowly, in
2–3 weeks, and are characterized by a raised surface and a
regular texture, glabbrous or finely branched, typically dark
violet in colour. Light microscopy reveals irregular hyphae and
arthroconidias.
Diagnosis of both the adult and children’s forms is reached




 It is then confirmed by a
direct microscopy study of a sample of the diseased hairs
plucked by tweezers and scales from the area. A culture in an
appropriate medium (SGA) is essential to establish the dia-




 The cultures are
fig. 1 A large alopecic patch 4–5 cm in diameter in the temporoparietal
zone.

















incubated for 30 days. After approximately 2 weeks, the charac-
teristic appearance of the colonies and their typical microscopic
morphology can be observed. The use of Wood’s light examina-




 infection, as this organism
does not fluoresece. A skin biopsy of the lesions is not necessary,
as the histopathological study will reveal the existence of
chronic or subacute dermatitis, with inflammation, follicular
destruction and sometimes suppurating folicullitis. The main
problem deriving from this illness is the destruction of the hair





 with the consequent mental and
emotional repercussions for the patient. In severely immuno-
suppressed individuals, systemic dissemination of the fungus has
been described.
The treatment of scalp tineas is carried out with topical
antimycotic agents, such as the imidazole derivatives, cyclopirox,
naftifine or terbinafine, used in conjunction with systemic





 In addition, an important associated measure
is frequent washing of the scalp and affected zones with an acid
pH soap or with a 2.5% selenium sulphide shampoo to avoid
the risk of the infection spreading by reducing the number of
viable spores. It is occasionally necessary to use oral antibiotics
and prednisone to prevent permanent alopecia in the inflam-
matory forms. In our study we opted for terbinafine ace both to








 in adults and the atypical





 Some authors even consider a possible diagnosis of





mycological study is essential to avoid late diagnosis and com-
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We report an immunocompetent adult patient with extensive
verruca vulgaris strictly confined to the major flexures.
A 55-year-old woman presented with a 5-month history of
progressively increasing multiple, asymptomatic, skin coloured
to brown, 2–10 mm, firm, papules with verrucous surface. The
lesions were exclusively present in the axillae, groins, medial
aspects of the thighs and pubic region (fig. 1). There were no
lesions on the labia majora, vagina, perianal region or else-
where. There was no history of genital ulceration or discharge.
There was no past history of any significant illness or intake
















of corticosteroids or immunosuppressive drugs or history
of similar lesions in her husband or other members of the
family.
General physical and systemic examination was within nor-
mal limits and gynaecological and per rectal evaluation did not
reveal any abnormality. The patient’s routine haemogram, liver
and renal function tests, blood sugar, urine analysis, stool for
occult blood, chest X-ray and ultrasound of abdomen were
normal. Enzyme-linked immunosorbent assay test for human
immunodeficiency virus infection was negative. Skin biopsy
from one of the papules in the right axilla confirmed the diag-
nosis of verruca vulgaris.
Common warts occur only infrequently on the genitalia,





males, they are almost always confined to the shaft of penis
where they retain their usual morphological characteristics and




 Flat lesions of
condylomata acuminata have occasionally been described on
the penile shaft, pubic skin and perianal region and groins.





 Verruca vulgaris confined to the axil-
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17Letters to the Editor
The evaluation of the effectiveness and side-
effects of a 200-mg/day constant dose of 
cyclosporin in chronic plaque-type psoriasis: 
can a constant dose be an alternative?
To the Editor
Cyclosporin A (Cyc-A) is known to be effective in the treatment
of psoriasis. However, dose adjustments may cause problems in
daily use. In this study, we examined the effectiveness and side-
effects of a constant dose of Cyc-A in chronic plaque-type
psoriasis.
Twenty-five patients who attended our clinic with both clin-
ical and histopathological features of psoriasis were evaluated.
All the patients had active, chronic plaque-type psoriasis lesions
and none of them had received any treatment for the past
2 months. One of the patients was excluded from the study after
the treatment protocol had started because of elevated liver
functions. The study was undertaken with 24 patients, of whom
11 were male and 13 were female. Their ages were between 19
and 66 years (mean age 42.29 ± 13.88 years).
All the patients were evaluated by physical examination every
2 weeks. A course of 200 mg/day Cyc-A (Sandimmune Neoral®
caps) was started (with a 12-h interval twice daily), regardless of
body weight. All the patients were followed-up for 4 months.
According to the clinical result, if successful, the dosage was
tapered down by 50 mg/day every 2 weeks.
Only blood-urea-nitrogen (BUN) levels were increased and
the psoriasis area and severity index (PASI) score decreased in
a statistically significant manner (P < 0.05, Wilcoxon signed t
rank test). During the study, two patients had insomnia and
three patients had hirsutism. Both side-effects were statistically
insignificant (χ2, P > 0.05).
Only one patient relapsed in the 1-month follow-up period
after the study was finished.
Powles et al. studied the effect of Cyc-A on 44 patients and
showed that 17 months of therapy with 3.3 mg/kg/day dosage
reduced the PASI score in 70.5% (n = 31) of the patients.1
Timonen et al. studied 457 psoriatic patients and found that
patients taking 2.5 mg/kg/day cyclosporin showed a 59%
regression, while the regression rate was 94% in patients taking
5 mg/kg/day at the end of 12 weeks’ follow-up.2 In our study,
we found 90% and more decrease in the PASI score in 83.3%
of our patients (20 patients). This was similar to results in the
literature.
The most serious side-effect of cyclosporin is nephrotoxicity
and hypertension. Although the BUN levels were increased sig-
nificantly in our study, all the values were in the normal range.
In addition, we did not encounter hypertension in our patients,
except for a patient who was already hypertensive from the
beginning. Her blood pressure was normal when using the drug
amlodipin.
From the literature it is known that serum lipids, and espe-
cially triglycerides, are increased during cyclosporin therapy.
Cutaneous malignities are also side-effects of Cyc-A. Hyperbi-
lirubinaemia, hypomagnesaemia and hepatic dysfunction can
also be seen in patients who use Cyc-A. One of our patient’s
hepatic enzymes increased fivefold during the fourth week of
therapy. The drug was stopped and the patient excluded from
the study. During the follow-up period, the liver enzymes
decreased to normal range in a few weeks. Except for this
patient, no hepatic side-effects were detected. There are some
other side-effects that are not life-threatening but alter the
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quality of life, such as tremor, headache, malaise, leg oedema,
hirsutism, parestaesia, gingival hyperplasia and anaemia. These
effects can be seen in 1–2% of the patients and especially in high
dosage users.3–7 We experienced insomnia in two and hirsutism
in three of our patients.
In the review of the literature the dosage of cyclosporin in
psoriasis patients is based on the patient’s body weight. We
aimed to study the effectiveness and side-effects of a constant
dose of Cyc-A in psoriatic patients. In conclusion, a 200-mg/day
constant dose of cyclosporin was found to be at least as effective
as the dosage used per kilogram in the literature on adult
psoriatic patients. Our patients did not experience any
nephrotoxicity, hypertension or cutaneous malignity. Malaise
and hirsutism were detected as minor side-effects. Our result
shows that the constant dose cyclosporin therapy is as effective
as the conventional usage of the drug. Constant dose
cyclosporin is an effective treatment, where no calculation is
needed, it is easy to administer and has few side-effects, and
provides a time-saving alternative treatment modality during
daily dermatological practice.
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17Letters to the EditorFatal aplastic anaemia in a patient with 
clarithromycin-induced toxic epidermal 
necrolysis
To the Editor
Clarithromycin is a macrolide antibiotic used for cutaneous and
respiratory system infections with a low frequency of adverse
effects.1 We present a case of fatal aplastic anaemia in a patient
with toxic epidermal necrolysis probably caused by clarithro-
mycin intake, which has not been reported previously.
A 65-year-old woman was admitted to our department for a
generalized rash, fever and malaise, following the third day of
clarithromycin intake. There was no history of clarithromycin
intake and allergy to any other drug previously. On physical
examination, her temperature was 39.5 °C, pulse rate 98 beats/
min and blood pressure 100/60 mmHg. Conjunctivas were
hyperaemic, and widespread erosions and ulcerations on oral
and genital mucous membranes were detected. Skin examina-
tion revealed an erythematous rash that consisted of confluent
macules, many of which had the appearance of irregular target
lesions distributed on the face, extremities and anterior chest
wall covering more than 50% of her body surface area. Nikol-
sky’s sign was positive on lesional skin. Laboratory tests revealed
a slight elevation of all liver enzymes; erythrocyte sedimenta-
tion rate 38 mm/h (normal range 0–20 mm/h); white blood
cell (WBC) count 4.98 × 103/µL [(4.5–11) × 103/µL]; neutrophil
3.574 × 103/µL [(1.5–6.7) × 103/µL]; haemoglobin 11.2 g/dL
(11.7–16 g/dL), haemotocrit 33.3% (35–47%); platelet count
187 × 103/µL [(150–400) × 103/µL]. There was no evidence of
any bacterial or viral infection. Histological examination of the
skin lesions revealed a subepidermal separation of the epider-
mis and dermis, numerous necrotic keratinocytes, ballooning
degeneration and lymphocytic exocytosis in the epidermis.
Based on the temporal relationship between drug exposure and
the onset of symptoms, a diagnosis of toxic epidermal necrolysis
(TEN) induced by clarithromycin was made, and clarithro-
mycin was withdrawn on admission. Methylprednisolone
64 mg/day and, in view of her pyrexia, imipenem 500 mg every
6 h intravenously were started as an empirical broad-spectrum
antibiotic therapy. Therapeutic measures also included
parenteral nutrition and maintenance of fluid and electrolyte
balance with regular skin, eye and mouth care. In the following
days, all parameters of the complete blood count gradually
decreased. Meanwhile her temperature fell to a subfebrile level
and imipenem was stopped on the 10th day of hospitalization.
However, on the 14th day her temperature started to increase
again and pancytopaenia with marked neutropaenia developed
(WBC 0.432 × 103/µL; neutrophil 0.134 × 103/µL; red blood
cell (RBC) 3.36 × 103/µL; haemoglobin 9.4 g/dL; platelet count
57 × 103/µL. Therefore, granulocyte colony-stimulating factor
(G-CSF; Filgrastim) 48 million units/day subcutaneously and
amikacin sulphate 500 mg twice a day and ceftazidime pentahy-
drate 2 g three times a day intravenously were started. However,
Letters 105
© 2004 European Academy of Dermatology and Venereology JEADV (2004) 18, 99–117
a progressive decrease in the complete blood count level contin-
ued, and a bone marrow biopsy showed that the marrow was
largely occupied by adipose tissue and the cellular component
had decreased (fig. 1). The patient’s condition gradually wors-
ened and she developed cardiopulmonary arrest on the 22nd
day of hospitalization. She was transferred to the intensive care
unit, but after 3 days she died.
TEN is a rare, life-threatening, acute mucocutaneous intoler-
ance reaction, usually representing a hypersensitivity reaction
to drugs, but it may also be caused by a variety of infections, or
have no clear cause.2 The most common offending drugs are
nonsteroidal antiinflammatory drugs (NSAIDs) sulphonamide
antibiotics, anticonvulsants and allopurinol.2,3 The exact
pathogenesis of the disease remains unknown, but it is regarded
as a cytotoxic reaction aimed at the destruction of keratinocytes
expressing foreign antigen.2,4
Aplastic anaemia is a clinical syndrome characterized by
insufficient production of marrow cells, bone marrow hypo-
plasia and pancytopaenia. Most cases of aplastic anaemia are
acquired. The disorder can be induced by some drugs such as
chloramphenicol, phenylbutazone, gold salts, penicillamine
and carbamazepine.4,5
Although TEN and aplastic anaemia affect different organs,
they may share a similar aetiology, at least in some cases caused by
drugs. The cellular immunological mechanism plays a substantial
role in both TEN and acquired aplastic anaemia.2,6 Although
some haematological abnormalities may be seen in the course
of TEN, such as anaemia, neutropaenia, lymphopaenia and
thrombocytopaenia,7 acquired severe aplastic anaemia associated
with TEN has been reported in only one case in the literature.4
The patient described herein developed TEN soon after the
start of treatment with clarithromycin, suggesting the possib-
ility of a triggering effect of this drug. Although imipenem
cannot be excluded as an aetiological agent in aplastic anaemia,
it is most probable that the immunological mechanism evoked
by clarithromycine that led to TEN is also responsible for the
occurrence of aplastic anaemia in our patient.
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200216(no issue no.)0Letter
Scabies in the elderly
To the Editor
Scabies can show atypical signs or symptoms in the elderly due to
a different immunological response; therefore, diagnosis is fre-
quently overlooked.1,2 Scabies epidemics are very common in
nursing homes.3 We present three cases of scabies in the elderly.
Case reports
Patient 1
A 90-year-old woman was hospitalized to evaluate a skin erup-
tion with severe itching of 1 month’s duration. At this time a
nosocomial outbreak of scabies had been noted in our hospital.
Examination revealed papulovesicular lesions on the abdomen
fig. 1 The hypocellular bone marrow (haematoxylin and eosin, original
magnification × 100).
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and erythematous plaques on the axillas and groins, but no
evidence of burrows. Routine laboratory tests showed eosino-
philia. Microscopic examination of scales obtained by skin
scraping was negative. We suspected scabies and 5% permethrin
cream was given. Cure was observed in a few hours.
Patient 2
During hospitalization in the Traumatology service due to a hip
fracture, an 88-year-old woman also presented with severe
pruritus and clumps of red papules on the trunk and some
burrows on the forearms. She was resident in a psychiatric
hospital and had been previously diagnosed with scabies. Re-
infestation by Sarcoptes scabiei was suspected and proven by
microscopy examination of scrapings. We recommended
isolation and treatment with scabicides (5% permethrin) not
only to the patient, but all symptomatic and asymptomatic
contacts.
Patient 3
A 75-year-old woman from the same ward and psychiatric
hospital as case 2 was referred to us because of pruritus and skin
eruption. On examination we observed papules on the
abdomen and back (fig. 1) and burrows on the palms (fig. 2).
Microscopic examination demonstrated many mites and eggs.
Five per cent permethrin cream treatment to the patient and
contacts was indicated.
Scabies is a cutaneous parasitosis caused by the mite Sarcoptes
scabiei var hominis. Affected persons have pruritus usually with
nocturnal exacerbation. Lesions consist of burrows, papules
and nodules on the axillary folds, nipple areola, peri-umbilical
area, buttocks and thighs. Secondary lesions may be found.
Inappropriate use of topical steroids may modify the clinical
picture mimicking other dermatosis (scabies incognito).4,5
Skin ageing and disturbed inflammatory response contribute
to an atypical presentation of scabies in the elderly. Papules
clustered on the trunk can be observed instead of burrows on
the hands, or typical burrows may be seen on unusual sites.
Lesions can be very keratotic or can be localized on the face,
scalp, palms, soles, elbows, knees and buttocks. The back is
frequently involved in these cases compared with the rare
involvement at this site in young patients. This is why scabies
in the elderly may be mistaken for other skin diseases such
as psoriasis, eczema, exfoliative dermatitis, drug reactions or
contact dermatitis.
According to Lyon and Fitzpatrick, three clinical variations of
scabies may be distinguished in the elderly:1 (i) cryptic cases with
pruritus but only minimal lesions; (ii) scabies incognito; and (iii)
Norwegian or crusted scabies containing huge number of mites.
Several nosocomial scabies outbreaks have been observed in
recent years. The lack of clinical suspicion for atypical scabies
in the index patient, often in elderly individuals, have resulted
in the epidemic.6
Permethrin is a pyrethroid synthetic with a very strong acari-
cide activity, which is proved to be safe, effective and well
tolerated. The probability of systemic effects is 40–400 times
lower than with Lindane 1%,7 which is why we have been using
this drug on our patients. A single oral dose of ivermectin
(0.2 mg/kg) has shown to be effective and well tolerated.8 This
treatment seems of great interest in particular varieties of
scabies (crusted scabies, immuno-compromised patients) or in
the case of community epidemics9.
In conclusion, we agree with Fraser-Andrews et al.,10 who
have recently reported three cases of scabies with clinical and
histopathological atypical features, in that we must keep a high
level of suspicion of this infestation and consider this diagnosis
in any elderly patient with pruritus.
fig. 1 Papules and papulovesicular lesions on the back.
fig. 2 Burrows on the palms.
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? 200317Letters to the Editor
Localized mucinosis subsequent to 
erysipelas
To the Editor
Erysipelas is a frequent cutis infection usually elicited by
Group A, β-haemolytic Streptococci.1 The diagnosis is orien-
tated to the main symptoms of erythema with flame-shaped
offshoots, fever and general malaise. Therapeutic success can
be assessed clinically on the basis of regression of the signs of
inflammation. Here we are reporting several cases of erysipelas
in which persistent infiltrated erythema in the area of the erysipelas
gave rise to a suspicion of therapy resistance. In each case, local-
ized mucinosis was determined histologically.
Between 1996 and 2001, out of 180 patients with erysipelas
receiving inpatient treatment in our hospital, seven female pati-
ents (3.9% of all erysipelas patients) developed clinically evident
localized mucinosis in the course of the disease. The mean age
was 64.7 years (± 17.8 years). Chronic lymphoedema was present
in three women, the others had previously been free of skin events.
Intravenous antibiotic therapy with 3 × 10 Mega Penicillin G
initially resulted in marked improvement in general well-being
in all cases. Clinically, however, infiltrated, sometimes pad-like,
yellow erythemas persisted in the area of the previous erysipelas
(5 × lower calf, 1 × foot, 1 × upper arm) (fig. 1). These covered
only part of the area affected by erysipelas. Under the assump-
tion of therapy-resistant erysipelas, a switch was made to other
antibiotics without any effect. Skin biopsies taken in all cases
because of the persistent erythemas revealed pronounced accu-
mulation of acid mucin in the papillary dermis (fig. 2).
In further examinations to identify the possible cause of
mucinosis, latent hyperthyreosis (reduced values of the thyroid-
stimulating hormone) was diagnosed in two patients. The thyroid
parameters were unremarkable in the other cases. In one case a
fig. 1 Pretibial mucinosis following erysipelas in a 66-year-old woman.
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first diagnosis of a previously unknown systemic scleroderma
was made. The localized mucinosis gradually abated in all cases
under local therapy with corticosteroids and compression.
Localized mucinosis subsequent to erysipelas has not, to our
knowledge, yet been described. However, there are reports in
the literature of the early twentieth century of changes in colla-
gen connective tissue in erysipelas. In 1921, Unna described the
transformation of the collagen connective tissue to a ‘homo-
geneous mass … (which) progresses to a maximum state of soft-
ness, from which an extremely hard-to-stain pulp forms which
is only amenable to resorption’ (cited in 2). This probably first
evidence of erysipelas-associated mucinosis was especially
observed following facial erysipelas. Considering this descrip-
tion, it seems possible that mucinosis is occasionally (perhaps
always subclinically?) associated with erysipelas. The patho-
mechanism that led to mucinosis is unknown. Both patholo-
gical stimulation of fibroblasts and impaired removal by the
lymphatic vascular system appear possible. Although we found
latent hyperthyreosis in two patients and systemic sclerosis in
another, no definite relationship between these diseases and the
mucinosis can be concluded. Furthermore, the topographical
pattern of mucin deposition (accumulation in the Stratum pap-
illare) in our cases does not correspond to pretibial myxo-
edema, which is characterized by mucin accumulation in
the lower dermis segments.3 The essential factor in the onset
of mucinosis seems, however, to be reduced lymphocapillary
drainage. These considerations are supported by the histolo-
gical agreement of our patient findings with those of Somach
et al.,3 who also found mucin deposition in the papillary dermis
in patients with stasis dermatitis. During erysipelas, lym-
phocapillary stasis is caused by an increased lymph-dependent
load, while the transport capacity decreases due to spasms,
paralysis or destruction of the lymph vessels.4
There is still no gold standard for the therapy of mucinosis;
it consists primarily in the recognition and treatment of any
underlying diseases. In addition, local treatment with glucocor-
ticoids (intralesional or as foil bandage) and compression may
be made,5 and these were also successful in our patients.
In summary, it can be stated that localized mucinosis mimics
the prolonged course of erysipelas. Mucin deposition seems to
be a result of impaired lymphocapillary drainage.
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16Letters
Bullous lichen sclerosus atrophicus
To the Editor
Lichen sclerosus et atrophicus is a rare, chronic, muco-
cutaneous disease of unknown aetiology. Onset can occur in
subjects of any age, but the condition is more prevalent in adult
females around the time of menopause than in males. The most
common site of the lesions is the anogenital area. The usual
symptoms are soreness and pruritus. Bullous lichen sclerosus et
atrophicus is an unusual form of the disease and the exact
prevalence is uncertain.
We report the case of a 53-year-old woman who had been
complaining of perineal burning and itching for about 1
month. Except for these symptoms she felt healthy and pre-
sented no associated immunological diseases. Physical exam-
ination revealed porcelain-white, atrophic, parchment-like
changes on the inner side of the labia majora and an erythe-
matous area with purpuric lesions, small telangiectasias and a
serohemorrhagic bulla on the perineum. No other pathological
lesions were observed on the woman’s skin or mucosa.
fig. 2 A 66-year-old woman. Haematoxylin–eosin stain. Subepidermal blister
and plate-like mucinosis in the Stratum papillare. Inset: Colloidal iron stain,
evidence of acid mucins.
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Routine biochemical and haematological analyses were nor-
mal. Unfortunately, for financial reasons we were not able to
perform the immuno-serological tests. Examination of a
bioptic specimen from the involved perineum indicated a dia-
gnosis of lichen sclerosus et atrophicus and we initiated treat-
ment with topical corticosteroids in the morning and oestrogen
in the evening. During the first month of therapy the pruritus
disappeared; 3 months later the woman developed new tiny,
linear, ivory coloured, atrophic lesions on the intergluteal cleft
but from then until now, 6 months later, the woman has been
free of pruritus and no new bullae have appeared although the
old lesions have not resolved completely.
Many factors, such as low sex hormone output, Borrelia
infection, chronic infections and trauma, have been suggested
as triggering factors for lichen sclerosus et atrophicus. The
increased prevalence of organ-specific antibodies and of associ-
ated autoimmune diseases suggests an autoaggressive aetiology.
A very interesting scenario was reported in the correspondence
published last year in the Journal of the American Academy of
Dermatology. Carlson and Murphy1 suggested that loss of
androgen receptor expression in lichen sclerosus may be a sec-
ondary phenomenon due to a change in squamous phenotype
rather than to hormonal pathogenesis. On the contrary, Clifton
and Smoller2 proposed that lichen sclerosus represents a focal
androgen insensitivity, as a result of random inactivation of the
androgen receptor gene. This inactivation may be triggered by
koebnerization, local infection, inflammation or any of the
other previously described associations with disease onset and
leads to receptor loss with disease progression. In their opinion
early treatment with topical testosterone may bind and stabilize
remaining receptors leading to regression of the lesions. If treat-
ment is delayed inactivation continues and a new phenotype is
expressed that no longer responds to topical testosterone
because all receptors have been lost.2 In addition to these
hypotheses, we found in the literature a small study about the
localization and level of androgen, oestrogen and progesterone
receptor expression in lichen sclerosus and in normal vulvar
skin. Androgen receptor was expressed in 12.8% of tissue
specimens of lichen sclerosus, oestrogen receptor in only one
patient, and progesterone receptor in none.3 These data show
that there is no evidence to date in support of the exclusive role
of any single factor in the pathogenesis of lichen sclerosus et
atrophicus.
Vulval bullous lichen sclerosus et atrophicus may be mis-
diagnosed as cicatricial pemphigoid, amelanotic malignant
melanoma, leukoderma or candida infection. In children it
can mimic (or be misdiagnosed as) sexual abuse. It has
been reported that bullous lichen sclerosus et atrophicus has
appeared on a morphea lesion. In such cases one must search
for lesions elsewhere on the trunk.
Lichen sclerosus et atrophicus is a chronic condition with
signs and symptoms that may wax and wane. Progression to
destructive scarring is common, but it is more important to
know that involved subjects face an increased risk of developing
vulvar or penile cancer.4,5
The treatment of choice for anogenital lichen sclerosus et
atrophicus is local application of a potent topical corticosteroid
for a limited time. Estrogen- or testosterone-containing creams
and topical retinoids can also be used. Circumcision may be
indicated in men, and surgery in women.4,6 Surgical therapy
is indicated when the lesions present signs of malignant
transformation or when medical treatment has failed; the three
main surgical procedures are vulvectomy, cryosurgery and laser
ablation.
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16Letters
Thyroid function and autoimmunity in 
children and adolescents with vitiligo
To the Editor
Vitiligo is a common disease that affects 0.5%−1% of the
human population, and it is more prevalent in females than
males. The disease manifests before 10 years age in 25% of cases
(and in infants as early as 4 months of age), before 25 years in
50%, and after the fortieth year in only 10%−15% of subjects.1,2
The frequent association of vitiligo with autoimmune thyroid
disease (ATD) is well known.1,3–5 The aim of this study was to
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assess the prevalence of thyroid dysfunction and autoimmunity
in children and adolescents with vitiligo.
We studied 61 children and adolescents with vitiligo, 35 girls
and 26 boys, 1.16–16.16 years old; the ages at the time of onset
of the disease varied from 0.32 to 16.16 years and disease dura-
tion ranged from 0.08 to 11 years. Family history was assessed
in 37 children and adolescents with vitiligo. The clinical variants
were as follows: vitiligo vulgaris, 54 (focal, eight; extensive,
two; stable, 36; progressive, eight) and halo nevi, seven. The
size and consistency of the thyroid gland, heart rate, arterial
pressure and skin humidity were evaluated. Thyroid function
tests included base levels of T3, T4 and TSH (FIA, Delfia) in 58
children and adolescents with vitiligo. TRH test was performed
in 22 children. Antithyroglobulin (TAT) and antimicrosomal
antibodies (MAT) were evaluated in the 58 children and adoles-
cents with vitiligo (microhaemagglutination method). Ultra-
sound examination of the thyroid gland (7.5 MHz transducer)
was carried out in 44 children. Cellular and humoral immunity
indices were evaluated in 15 children with vitiligo and 26 con-
trol children. Variation analysis (Student-Fisher’s t-test) and
graphic analysis were used.
There was a family history for thyroid disease in 16 of 37 chil-
dren, diabetes mellitus in 22 of 37 children, vitiligo in eight of
37, alopecia areata in five and rheumatoid arthritis in two.
There was a two-fold female prevalence of thyroid disease and
diabetes. Thyromegaly was present in 31 children (23 girls and
eight boys), 17 with degree IA, 11 with degree IB, and three with
degree II. The thyroid consistency was soft in 23 children
(74.5%) and firm in eight (25.8%). The skin was normally
moist in 39 children, dry in nine and excessively moist in two
children with thyrotoxicosis. An accelerated heart rate and
increased blood pressure were registered in only two children
with thyrotoxicosis. Thyroid function was assessed in 58
children and adolescents with vitiligo with the following
findings: hyperthyroidism in three children, subclinical
hypothyroidism (SH) in five and euthyroid function in 50
(P < 0.001) (Table 1). TRH test carried out in 22 cases showed
a hypothyroid type response in six children and a normal
response in 16 (72.7%). TAT and MAT titres were increased
in 29 children (fig. 1). Ultrasound examination of the
thyroid gland revealed abnormalities typical for autoimmune
thyroiditis (AT) in four children, suggestive for AT in 11 and
typical for thyrotoxicosis in two. ATD was diagnosed in 32
children (29 children with AT and three with thyrotoxicosis).
Neck lymphadenopathy was found in only four children. The
evaluation of the cellular and humoral immunity parameters
in children with vitiligo and AT revealed decreased numbers of
cytotoxic Ly (TLy), an increase of activated TLy and decreased
cells with natural killer activity (P < 0.001–0.01).
It is still unclear why vitiligo manifests as spotty depigmenta-
tion (segmental, symmetric or total) in the presence of auto-
antigen against all melanocytes. The greater incidence of vitiligo
in females in our study correlates with the commonly accepted
view.2 The family prevalence of a number of autoimmune
endocrine and systemic diseases in vitiligo supports the hypo-
thesis for its autoimmune genesis. The presence of thyromegaly,
antithyroid antibodies and thyroid dysfunction in significant
numbers of our patient cohort indicates frequent involvement
of the thyroid gland in vitiligo, as reported previously.6–8 Some
authors have observed that thyroid gland involvement in vitiligo
increases with age,9 while others have reported no correlation
between functional thyroid disorders, patient’s age and the
duration of vitiligo.8 There was no correlation between the
positive titre of thyroid antibodies and the abnormal TRH
responses in our vitiligo subjects, contrasting with the findings
reported by Betterle.10 The fact that in 40% of cases we found an
atrophic type of autoimmune thyroiditis is of interest. The find-
ing that the thyroid function abnormalities in our children were









Healthy children (controls) 2.02 ± 0.58 118.2 ± 21.12 1.88 ± 0.87
n = 118 n = 138 n = 162
Children with vitiligo and 
normal thyroid function
3.24 ± 0.94 117.9 ± 19.44 1.66 ± 0.65
n = 11 n = 41 n = 50
P = NS P = NS P = NS
Children with vitiligo and 
subclinical hypothyroidism
3.16 ± 1.22 133.92 ± 12.24 5.41 ± 1.67
n = 3 n = 4 n = 5
P = NS P = NS P < 0.001
fig. 1 Thyroid auto-antibodies in children with vitiligo.
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subclinical emphasizes the need to assess thyroid function in
subjects with vitiligo. The changes in the indices of cellular
immunity in our children suggest the participation of several
types of TLy in the pathogenesis of the autoimmune process in
vitiligo. The increase of activated TLy in the peripheral blood
and the presence of infiltrates of these lymphocytes in the skin
and the thyroid gland in vitiligo subjects is well established. It
has been suggested that the epithelial cells express the aberrant
HLA-DR antigen.4 Our study emphasizes the prevalence of
thyroid gland pathology in children with vitiligo.
We recommend that thyroid gland function be assessed
annually in children with vitiligo. The early diagnosis of clin-
ical and subclinical forms of thyroid disease in these children
facilitates early treatment and avoidance of the phenotypic
manifestations of hypothyroidism.
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16Original ArticleTreatment of Pityriasis rosea with UVBValkov  e al.UVB phototherapy for Pityriasis rosea
To the Editor
Pityriasis rosea (PR) is a common, self-limiting, eruptive
erythemo-scaling disease that begins with the appearance of an
initial plaque most often on the trunk, followed in about a week
or two by the development of an analogous spotty rash.
The aetiology of the disease is still unknown (probably
viral),1 and it cannot be treated causally. Merchant and
Hammond in 19742 were among the first to promote the idea of
the therapeutic effect of ultraviolet (UV)B rays on PR but the
reports concerning this problem are still few.2–7
In the present study we wanted to verify the therapeutic effect
of UVB rays on PR and to devise rapid and successful methods
for UVB phototherapy of the disease.
The study included 101 patients: 53 (52.5%) women,
34 (33.7%) men and 14 (13.9%) children. All were in good
health, with no data for photosensitivity and with negative sero-
logical tests for syphilis. The duration of the disease before the
beginning of the treatment varied between 7 and 25 days. The
patients were with phototype II–IV. In seven of them (6.9%)
irritation of the rash was observed.
The severity of the disease was determined according to the
Pityriasis Rosea Severity Score (PRSS).6 Three target symptoms
− erythema, infiltration and scaling − were assessed with the
use of a scale from 0 to 3. Depending on PRSS values the
patients were divided into two groups; those with light to
moderate (PRSS < 15) and those with severe (PRSS > 15) forms
of PR. To assess any effect of the UVB phototherapy the index was
determined at the beginning and at the end of the treatment.
The irradiation sessions were held in a conventional UV
cabin (Waldmann 7001 K). Two groups of patients were formed.
The first one comprised 24 (23.8%) people. The initial dose of
the irradiation was 80% minimal erythema dose (MED). It was
increased according to the degree of the preceding erythema.
Only the right half of the body was irradiated with UVB. UVA
(1 J/cm2) was given as a placebo to the left half of the body
(Table 1). The second group consisted of 77 (76.2%) patients.
The UVB irradiation was applied to the whole body. The initial
UVB dose was determined according to the phototype (Table 1).
The procedures were held four times weekly. During the
treatment course the patients did not receive any systemic
Table 1 UVB dosage in Pityriasis rosea therapy
UVB dose ( J/cm2) Ist group n = 24 2nd group n = 77




Slight erythema Same dose
Intense erythema No irradiation
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drugs. The topical therapy included only emollients to prevent
skin dryness.
Our experience confirmed that the UVA irradiation in the
dose mentioned earlier had no effect on the course of the dis-
ease but significant clinical improvement according to PRSS
(t = 17.9; P < 0.001), with total clearing of the rash was
observed after UVB phototherapy (Table 2). The analysis of
the data showed a statistically significant difference between
the mean number of procedures (t = 4.47; P < 0.0001) and the
mean dose of UVB (t = 3.85; P < 0.0001) necessary for total
recovery of patients with PRSS more than and less than 15. The
procedures and the dose of UVB increase with the severity of the
disease. It is worth noting that in one woman in whom intensive
erythema was observed after the first irradiation, no continua-
tion of the treatment was necessary and the rash cleared with
only one procedure.
The correlation analysis confirmed the connection between
the duration of the disease and duration of UVB therapy
(r = 0.18; P = 0.05). The number of procedures necessary for
total recovery could be determined with the help of regression
analysis (linear model: y = a + bx). The following equation
could be used:
Number of procedures = 4.34 + [0.05 × duration of the disease 
(in days)].
No significant side-effects were noted during the treatment
course except for slight tenderness and dryness of the skin.
The present study demonstrates that the application of
broadband UVB in patients with PR substantially decreases the
severity of the disease and can result in total recovery. UVA
irradiation did not change the course of the disease. This is not
surprising as it is known that 1000 times greater doses of UVA
are necessary to reach the effect of UVB.
The results presented are in accord with previous bilateral
comparison studies in which 5–10 consecutive erythemogenic
UVB exposures resulted in decreased extent of the disease.3,6
The established correlation between the duration of PR and the
number of procedures necessary for total recovery confirms the
observations of other authors.3
The necessity of a greater number of UVB sessions in patients
with more severe forms of the disease may be due either to
greater values of PRSS or to a higher phototype or the presence
of lesions on the lower extremities that are in general more
resistant to UV light.
The aetiology of PR is still unknown, as is the mechanism of
the therapeutic effect of UVB irradiation. Some authors
presume that a cell-mediated immune mechanism with increased
numbers of Langerhans cells may be important in PR patho-
genesis.8–10 The suppression of cell-mediated immune response
and modification of the number and function of Langerhans
cells in the skin following UV irradiation may at least partly
explain the beneficial action of UVB light on this disease.
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UVB in J/cm2before phototherapy after phototherapy
< 15 (n = 72) 9.01 ± 3.76 0 4.7 ± 2.3 0.62 ± 0.42
> 15 (n = 29) 20.69 ± 6.9 0 6.8 ± 2.9 1.12 ± 0.68
Total (n = 101) 12.37 ± 6.9 0 5.3 ± 2.7 0.76 ± 0.55
Table 2 Results from UVB phototherapy of PR
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16Letters to the EditorDiscoid lupus erythematosus: clinical and 
pathological study of 24 patients
To the Editor
From 1996 to 2001 we examined in our department 24 subjects
with discoid lupus erythematosus (DLE) (19 females and 5 males,
age range 22–77 years, average age 55.5 years), who presented
with scalp involvement, most frequently on the vertex (87%).
Fifteen of these subjects showed an exclusive scalp localization
(fig. 1). The average age of onset of the scalp lesions was
53.6 years and the average duration of the disease 27 months.
Nine subjects presented with a single localization on the
scalp and 15 presented with multiple localizations. ANA were
positive, with a titre of 1 : 160 in one subject, with negative ENA
and n-DNA. All the subjects were treated first with topical
steroids, and synthetic antimalarials were administered to
poor responders. Subjects who did not respond to either of
these therapies were treated with oral steroids. Five subjects
responded positively to the treatment with topical steroids.
The 19 subjects who did not respond were treated with a
combination of topical steroids and synthetic antimalarials
(during spring and summer, repeated for up to 3 years, as
recommended in the literature), and eight of these showed
a positive response. The 11 non-responders were treated with
oral corticosteroids (up to 0.5 mg/kg/day methylprednisolone
or up to 0.5 mg/kg/die prednisone, with rapid tapering), and
seven of these subjects showed improvement. Recurrence after
suspension of the therapy was observed in 10 cases, limited,
however, to cases treated with only topical therapy. Overall we
observed an improvement in 15 of the 24 subjects treated.
Direct immunofluorescent examination showed granular
deposits of immunoglobulin (Ig)G around the follicles and at
the dermo-epidermal junction in 16 of the 24 subjects. DLE
is a chronic condition, characterized by neatly demarcated
plaques that are red, atrophic, and scaly and on sun-exposed
areas.1
This disease represents 40% of all inflammatory conditions
causing scarring alopecia.2,3 The etiopathogenesis is not
completely understood, but some of the most probable
causes are genetic predisposition, the immune system and other
endogenous and exogenous factors.4,5 The scalp is involved in
30–40% of cases.5
When the inflammatory phase fades it leaves a scarring
alopecia due to destruction of the follicles by the inflammatory
processes. This alopecia can cause aesthetic problems and the
chronic forms might degenerate, after a 20–30-year latency,
becoming cutaneous neoplasms, including basal cell and
squamous cell carcinomas.6,7
The therapy is based on the use of topical, intralesional or
systemic steroids; synthetic antimalarials are also frequently
used as well. In the literature good results have been reported
using azathioprine, etretinate, thalidomide and alpha interferon.
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16Letters to the Editor
Pigment anomaly caused by calcipotriol in 
a subject with melanoma
To the Editor
We report the case of a 63-year-old Caucasian male with
melanoma who developed naevus spilus-like lentigines
following therapy with topical calcipotriol on psoriatic plaques.
The man was admitted to hospital in 1998 with a pigmented
tumour on his left calf. Excisional biopsy revealed a superficial
spreading melanoma (Clark III. Breslow 2.279 mm). After
surgical removal of his primary tumour and metastatic lymph
nodes, dacarbazine monotherapy was administered for 6 months.fig. 1 Scarring alopecia due to discoid lupus erythematosus.
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The man also had psoriasis, which had started when he was
31 years old. His psoriasis had been treated only with topical
steroids, and he had not received phototherapy or any other
immunosuppressive treatment. During the chemotherapy his
psoriasis worsened considerably, therefore we changed his top-
ical steroid treatment to calcipotriol ointment. Two months
after the beginning of calcipotriol therapy, we observed the
appearance of small dark brown macules within symmetrical,
sharply demarcated, large, light brown macules on his buttocks
and extremities (fig. 1). These abnormal, lentiginous skin pig-
mentations were localized on the psoriatic plaques treated with
calcipotriol. A punch biopsy specimen was taken. Histopatho-
logical examination evidenced focal melanin pigmentation in
the basal layer of the epidermis with hyperproliferation of small
vessels and slight mononuclear cell infiltration in the papillary
dermis (fig. 2). Gomorri’s stain confirmed that the pigment was
melanin. No psoriatic change was seen in the specimen.
Two years after the end of both chemotherapy and calcipotriol
treatment this lentiginous pigment anomaly is still present.
Calcipotriol is known to cause a local irritative reaction
in the skin,1 which could lead to the development of post-
inflammatory pigmentation. The appearance of hyperpig-
mentation or lentigines have been documented as a side-effect
of phototherapy alone2,3 or combined with calcipotriol.4,5 There
have also been reports of the appearance of multiple lentigines
within healing psoriatic lesions in subjects not treated with
PUVA or UV-B therapy.6 Ours is the first report on the devel-
opment of lentigines following calcipotriol therapy alone.
Some authors have reported that 1,25-dihydroxyvitamin D3 is
involved in the regulation of melanin synthesis and melano-
cytes have been shown to express 1,25-dihydroxyvitamin D3
receptors, but their exact role in melanogenesis is not yet
clear.7,8
As subjects with melanoma are known to have a tendency to
develop hypopigmentation and/or hyperpigmentation,9,10 it is
possible that the calcipotriol caused the pigment anomaly in
our patient, and that this was also related to his melanoma.
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16Letters to the Editor
Partial response to treatment with 
recombinant interferon-alpha2a in an adult 
patient with tufted angioma
To the Editor
Tufted angioma (TA) is a rare benign cutaneous vascular
proliferation with typical clinical and histological features.
More than 40 of the 260 cases reported in the literature were
from Japan.1 Onset of the disease was below 5 years of age
in half of these patients and below 10 years in the other half.
Few cases of adult onset have been reported. The treatment
of the disease is difficult; surgical excision is often followed
by recurrence, and the results obtained with steroids, cryo-
therapy, radiotherapy and laser therapy are not encouraging. We
report the case of a 28-year-old woman affected by tufted angi-
oma and treated with interferon-alpha2a (IFN-α2a). In this
case the treatment with recombinant IFN-α2a seemed to be
only partially effective.
The 28-year-old woman presented to our department in Feb-
ruary 1996 with painful red patches, two of which measured
3 × 2 cm, on the neck. The patches had appeared 2 years earlier
and had grown in size. They were roughly oval in shape, raised
with respect to the surrounding skin and had well-defined mar-
gins (fig. 1). Histological examination of a bioptic specimen
showed substantially normal epidermis overlying a prolifera-
tion of cells in the middle and deep dermis. The cells were
endothelial cells and pericytes arranged in typical ‘cannon ball’
disposition. Typical ‘clefts’ were observed in the cell prolifera-
tion and their margins. Compact vascular lobules were
separated by apparently normal connective tissue. Immunohis-
tochemistry showed positivity for CD31 and actina. A diagnosis
of TA was made but the woman refused surgical treatment,
which would have been problematic given the site and size of
the lesions. She was treated with systemic recombinant IFN-
α2a (3 million (international) units (MU) three times a week),
but treatment was suspended after 1 month because of signi-
ficant side-effects (flu syndrome, headache, abdominal pain,
nausea, asthenia). However, the pain ceased and the lateral
spread of the lesions was arrested. Treatment was continued
with intralesional IFN-α2a (1 MU three times a week for
8 months) without significant side-effects. At follow-up after
1 year the lesions were substantially unchanged.
Tufted angioma, also known as ‘progressive capillary
haemangioma’ or ‘Nakagawa’s angioblastoma’ was first
described by Nagakawa as ‘angioblastoma’ in 1949.2 In 1976,
Wilson Jones introduced the term tufted because of the
typical histological pattern of grouped dermal capillary
‘tufts’.3 TA is clinically characterized by the development of
painful, bright red, smooth-surfaced macules, papules or
nodules with well-defined margins, and by an initial growth
phase with lateral extension, lasting from a few months to
about 10 years. The most frequent sites are the neck, upper
trunk and shoulders. Rarely, TA can regress spontaneously.4
Differential diagnosis is necessary with special attention to
Kaposi’s sarcoma, late-onset angiosarcoma, angiomatous
eccrine hamartoma and bacillary angiomatosis. Only histolog-
ical examination allows certain diagnosis of TA. Labelling
fig. 1 Red patches of angioma on the neck before therapy.
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of biopsy specimens with anti-Ulex Europaeus, antifactor VIII
and antivimentin antibodies and enolase (EN4) to identify
endothelial cells, and with anti-actin-a antibodies specific for
smooth muscle, as well as positivity for CD31, indicate
endothelial cell immaturity and the presence of two cellular
components (muscle and vascular) in the angioma.5 The etio-
pathogenesis of TA is still unclear; however, cases of TA occur-
ring during pregnancy suggest that high oestrogen levels may
promote vascular proliferation in TA, as in spider naevi and
pyogenic granuloma.6,7
As yet there is no elective treatment for TA. Surgical excision
is often followed by recurrence, and the results obtained
with cryotherapy, radiotherapy and laser therapy8 are not
encouraging. High doses of oral prednisone (2 mg/kg/day)
were reported to reduce lesion volume and IFN-α2a was
also used when surgery was contraindicated or in life-
threatening childhood forms of TA associated with Kasabach–
Merritt syndrome and/or refractory to steroid therapy.9,10
Interferons are a good option for the therapy of some
invasive angiomatous diseases, such as haemangiosarcoma,
Kaposi’s sarcoma and life-threatening haemangioma. The
exact mechanism by which these intercellular signalling pro-
teins are effective in vascular diseases is not completely clear.
However, it is know that IFNs inhibit migration and prolifera-
tion of endothelial cells, decrease platelet aggregation and
seem to limit production of factors stimulating angiogenesis,
such as basic fibroblast growth factor (bFGF).11 Partial or
complete remission has been obtained in children with TA
with administration of subcutaneous or intralesional IFN-α
at doses between 0.5 and 3 MU per day or 3–4 times a week
for 2–7 months.5,10–12 To our knowledge, this is the first case of
an adult treated with IFN, and the treatment with systemic
recombinant IFN-α2a seemed effective, because the pain ceased
and lateral spread of the lesions was arrested, but there were
major side-effects. Intralesional therapy produced no further
significant improvement. We cannot say whether this partial
response was due to an insufficient dose of IFN or to low sus-
ceptibility of the TA to this drug.
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16Letters
CagA seropositivity in Helicobacter pylori 
positive patients with psoriasis
To the Editor
Helicobacter pylori (HP) is considered a major pathogenetic
factor in chronic gastritis, peptic ulcer disease, gastric adenocar-
cinoma and low-grade gastric MALT lymphoma. Strains of HP
that express the cytotoxin-associated gene A (CagA) have been
associated with a more virulent disease and may influence the
clinical outcome of the infection. Recently, a debate about the
association between HP and various dermatological conditions,
including psoriasis (Ps), has been reported.1 Although some
evidence does not support a strong association between HP
and Ps,2–4 the nature of this relationship might differ when the
virulence of the infecting strains is examined.
We have investigated, in a prospective case-control study, the
seroprevalence of CagA in HP-positive patients with Ps.
Eleven patients (eight males, three females, mean age
40.5 years, range 17–63 years) were randomly selected from a
total of 62 HP-infected patients with Ps. All of the patients,
except one with guttate Ps, had the chronic plaque type of dis-
ease. Eight of these had a severe disseminated disease involving
the head, trunk and extremities. Two patients had psoriatic
arthritis. Duration of Ps extended from 3 months to 40 years
(mean 19.4 years). Two patients were under treatment with
cyclosporin and one with acitretin. Twenty-two sex- and age-
matched HP-positive subjects with endoscopically confirmed
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non-ulcer dyspepsia (NUD), living in the same area, were used
as controls. None of the controls had been treated for eradica-
tion of HP before enrolment, or had Ps. The presence of ulcers
or any gross gastrointestinal lesions had been ruled out by
endoscopy.
Western blotting using surface antigens of the organisms
(Bioblot Helicobacter®, Biokit SA, Spain) was applied to
determine serological HP infection (positivity of at least 35,
89 or 116 kDa single bands, or positivity of at least two of the
19.5, 26.5 or 30 kDa bands) and anti-CagA HP specific
immunoglobulin G (IgG) antibodies. To study the association
between CagA seropositivity and Ps/controls, Fisher’s exact test
was used. Informed consent was obtained from all patients and
controls.
Six of 11 patients (54.5%) with Ps were CagA seropositive, in
contrast to 15/22 (68.1%) NUD controls (P = 0.47, odds ratio
0.57, 95% CI 0.1–3.14). CagA status was not associated with
duration of disease, type and severity of psoriasis or presence
of arthropathy. The two psoriatic patients who were under
immunosuppressive treatment (cyclosporin) when the test
was performed were CagA positive.
Although most HP infections are clinically silent, the organ-
ism is associated with substantial morbidity and mortality.
Among the known HP virulence factors, CagA status is
included. CagA-bearing HP strains induce a stronger
inflammatory response and are strongly associated with
peptic ulceration and gastric cancer.5,6 Although controversial,
the association of CagA-positive HP infection with different
extradigestive conditions such as acute myocardial infection,
autoimmune thyroid disorders or rosacea has been reported in
case-control studies, suggesting that CagA positive strains
might play a role in the development of these diseases.7–9 In
our study, patients with Ps showed a CagA seropositivity of
54.5%, lower than 68.1% of NUD controls (non-significant
differences). In a review of the literature, the CagA seropreva-
lence both in NUD patients and in the general population differ
greatly among the geographical localizations. In most of the
studies performed in Western Europe, the CagA seropositivity
in HP-positive NUD patients ranges from 45% to 70%,10–12
compared with 29% to 61% in the apparently healthy general
population infected with HP.10,12,13 It is controversial whether
the differences between the two groups of population are signif-
icant or not. The CagA seroprevalence of our study is included
among the rates of both groups of population, which suggests
that the more virulent CagA positive strains of HP seem not to
be strongly associated with Ps.
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